Public health impact and return on investment of the pediatric National Immunization Program in Italy
The benefits of the Italian pediatric NIP, including averted disease-related morbidity, mortality, and associated costs, highlight the value of continued investment in pediatric immunization.
Authors
- Justin Carrico (ORCID: https://orcid.org/0000-0002-4659-9309)
- Claire E. Mellott (ORCID: https://orcid.org/0000-0003-0513-0990)
- Angela Bechini (ORCID: https://orcid.org/0000-0002-6013-8779)
- Francesca Senese
- Sara Boccalini (ORCID: https://orcid.org/0000-0002-9695-7549)
- Marco Barbieri (ORCID: https://orcid.org/0009-0007-0111-1246)
- John Lang (ORCID: https://orcid.org/0000-0002-1770-2995)
- Goran Benčina (ORCID: https://orcid.org/0000-0001-6293-8211)
- Sandra E. Talbird (ORCID: https://orcid.org/0000-0003-4719-3703)
- Paolo Bonanni (ORCID: https://orcid.org/0000-0003-2875-3744)
Institutions
- Leeds and York Partnership NHS Foundation Trust (GB)
- Triangle (US)
- Merck Canada Inc. (Canada) (CA)
- MSD (Italy) (IT)
- RTI Health Solutions (US)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- MSD (Spain) (ES)
- University of Florence (IT)
- University of York (GB)
Publication Details
- Journal
- Expert Review of Vaccines
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1080/14760584.2024.2411425
- Citations
- 3
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 1.16